Table 1.
Patient demographics and baseline clinical characteristics
| Characteristics | Treatment group | Untreated group | P |
|---|---|---|---|
| Sex | |||
| Male | 11 | 8 | .180 |
| Female | 9 | 2 | |
| Smoking history (%) | |||
| Smoker | 12 | 9 | .204 |
| Nonsmokera (or unknown smoking history) | 8 | 1 | |
| Median age (years) | 67 | 66 | 1.000 |
| ECOG PS | |||
| PS = 3 | 15 | 7 | 1.000 |
| PS = 4 | 5 | 3 | |
| Metastatic site | |||
| Bone (spine) | 10 | 6 | .816 |
| Brain | 9 | 4 | |
| Extrapulmonary | 6 | 2 | |
| Complications | |||
| Hemoptysis | 1 | 2 | |
| Respiratory failure | 1 | 1 | |
| Comorbidities | |||
| Cerebral infarction | 1 | 1 | |
| Multiple pulmonary bullae | 1 | 2 | |
| Serum tumor markers | |||
| Serum T‐SPOT® negative | 20 | 10 | |
| CEA | 15 | 8 | |
| CA 211 | 11 | 3 | |
| CA50 | 4 | 1 | |
| CA19‐9 | 5 | 2 | |
| NSE | 3 | 1 | |
| CA15‐3 | 2 | 2 | |
| CA242 | 2 | 1 | |
| Osteocalcin, N‐MID® | 2 | 3 | |
| ≥3 types | 8 | 3 | |
| ctDNA results | |||
| EGFR Exon19 del NGS | 5 | ||
| EGFR Exon19 del ARMS | 4 | ||
| EGFR Exon21 L858R NGS | 3 | ||
| EGFR Exon21 L858R ARMS | 7 | ||
| Complex mutations NGS | 1 | ||
Abbreviations: CA, cancer antigen; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; NSE, neuron‐specific enolase.
a
Lifetime smoking history of fewer than 100 cigarettes.